{"id":47586,"date":"2023-03-21T11:58:54","date_gmt":"2023-03-21T11:58:54","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=47586"},"modified":"2023-04-01T05:24:15","modified_gmt":"2023-04-01T05:24:15","slug":"effective-combinations-against-efflux-pump-overexpressed-on-azole-resistance-candida-and-dermatophytes-a-systematic-review","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol16no1\/effective-combinations-against-efflux-pump-overexpressed-on-azole-resistance-candida-and-dermatophytes-a-systematic-review\/","title":{"rendered":"Effective Combinations Against Efflux Pump Overexpressed on Azole Resistance Candida and Dermatophytes: A Systematic Review"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

The development of resistance against antifungal therapy is the primary emerging challenge for the coming era. Many fungus species may develop resistance to antifungal drugs after prolonged exposure, prophylaxis therapy and irrational use.1<\/sup> Resistance may arise from overexpression of genes encoding efflux pumps, overexpression of efflux pumps, reduced drug import into fungal cells, and overexpression\/ alteration\/ reduced affinity of target enzyme [14-alpha demethylase] towards antifungal drugs. Efflux pumps are commonly present on fungal cells for detoxification and extended exposure to antifungal drugs; these efflux pumps and associated genes are over-expressed. Consequently, antifungal drugs are actively flushed from fungal cells and resistance develops in susceptible fungi. Dermatophytes & yeasts, mostly Candida<\/em> are the common fungi known for overexpression of efflux pumps, ABC (ATP binding cassettes) and MFS (major facilitator super family), and genes which are responsible for coding of these efflux pumps are mainly CDR1, CDR2 (Candida drug resistant gene) MDR1( Multi drug resistance) FLU1(Fluconazole resistance).2-3 <\/sup><\/p>\n

Infection with resistant species is predominantly observed in immunocompetent and immunocompromised patients, where the host’s immune status plays a significant role in the outcome. Chronic conditions with considerable morbidity rates can be severe in immunocompromised patients and result in invasive infection.<\/p>\n

Candida<\/em> is an opportunistic fungal pathogen, affecting the nails, skin, and oral and genital mucosa. Certain conditions like diabetes4<\/sup>, genetic disorders, and circulatory diseases impact the immune system, and such patients are at high risk of getting fungal infections.<\/p>\n

Dermatophytes are a group of related fungi belonging to the three main categories, i.e.\u00a0 Epidermophyton, Trichophyton<\/em>, and Microsporum<\/em>.\u00a0Two new classes i.e. Lophophyton<\/em> and Nannizia <\/em>were included according to the new proposal of phylogenetic taxonomy.5<\/sup> Dermatophytosis is a superficial infection of hair, skin and nail caused by dermatophytes. Most commonly, it is caused by Trichophyton genus.6<\/sup> The prevalence of both these infections is high worldwide and, if not treated appropriately, could lead to invasion into the deeper layers of skin and resistance.<\/p>\n

Treatment\/therapy<\/strong><\/p>\n

Two major classes of antifungal agents active against susceptible strains of Candida and dermatophytes uniformly, have been detailed in Table 1. For cutaneous infection, topical therapy is preferred and for extensive infection, systemic treatment.7<\/sup> In general, topical therapy shows fewer side effects. The side effects are dose-related, dependent on the length of treatment and route of administration.<\/p>\n

Table 1: Details of commonly used antifungal drugs, their mechanisms and adverse effects<\/strong><\/p>\n\n\n\n\n\n
SN<\/strong><\/td>\nAntifungal agent<\/strong><\/td>\nMechanism of action<\/strong><\/td>\n\u00a0\u00a0\u00a0\u00a0 Adverse effects<\/strong><\/td>\nReference <\/strong><\/td>\n<\/tr>\n
1<\/td>\nClass: Imidazoles<\/strong><\/p>\n

Bifonazole, Clotrimazole, Econazole,<\/p>\n

Ketoconazole, Luliconazole,<\/p>\n

Miconazole, Sertaconazole, and<\/p>\n

Tioconazole<\/td>\n

Block the synthesis of ergosterol, alter the cell membrane permeability of fungi<\/td>\nGastrointestinal disturbances like nausea, vomiting, abdominal pain, diarrhea and nephrotoxicity, hepatotoxicity photosensitivity, and\u00a0 neurotoxicity<\/td>\n[7]<\/td>\n<\/tr>\n
2<\/td>\nClass: Triazole<\/strong><\/p>\n

Fluconazole, Isavuconazole,<\/p>\n

Itraconazole, Posaconazole,<\/p>\n

Ravuconazole, Voriconazole,<\/p>\n

Luliconazole,and Lanoconazole<\/td>\n

Interruption of conversion of lanosterol to ergosterol<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Among azoles, fluconazole (FLC) and itraconazole (ITZ) are the safest drugs. Both are triazoles and inhibit cytochrome P450 14\u03b1 lanosterol demethylase. Compared to FLC, ITZ had a much lower MIC (Minimum Inhibitory concentration) value. On long-term azoles exposure unfortunately, there are an increasing number of resistant strains of Candida spp.<\/em> and dermetophytes.8-9<\/sup> The strains found to be resistant to FLC include Trichophyton tonsurans <\/em>(T. tonsurans<\/em>), Microsporum canis<\/em>, Microsporum gyp<\/em>. and Trichophyton rubrum<\/em> (T.<\/em> rubrum<\/em>).8<\/sup> The resistance was mediated by TruMDR2, TruMDR1, and ABC\u00a0 for FLC, and in the case of candida Cdr1p and\/or CaMdr1p belonging to the ABC and MFS superfamilies. Among dermatophytes, T. rubrum<\/em> prevalence increased in the past few years. Yamada et al<\/em>., (2021) proposed that ITZ resistance in T. rubrum<\/em> was mediated by ABC transporter TruMDR2 and, to a small extent, by TruMDR3genes.9<\/sup><\/p>\n

Studies indicate that the Azole class of drugs exhibits resistance by various mechanisms, primarily overexpression of the efflux pump. Azoles bind to cell efflux transporter proteins and are expelled from the cells. Overexpression of these efflux pumps can lead to treatment failure. Another reason might be the mutation of Erg II gene, which is responsible for drug target modification.8, 10<\/sup><\/p>\n

The major mechanisms of antifungal drug resistance and possible ways to overcome it are depicted in Figure 1.<\/p>\n\n\n\n
\"Vol20No1_Eff_Ais_fig1\"<\/a><\/td>\nFigure 1: Mechanism of antifungal drug resistance and possible ways of overcoming efflux-mediated azole drug resistance: <\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The development of new antifungal drugs requires more time and efforts. Researchers are trying to resolve the problem of resistance in several ways; combination therapy is one of them.11-12<\/sup> For a decade, many compounds, including phytoconstituents combined with standard antifungal drugs, were found to be effective against resistant strains of fungus, but these areas are less explored. Other advantages of combination therapy include reduced toxicity, fewer side effects compared to the single drug prescribed at a high dose, and enhanced antifungal effects.<\/p>\n

In combination therapy, one molecule may sensitize fungal species against antifungal drugs primarily by blocking efflux pumps like ABC and MFS in which ABC is most often found to be overexpressed. These are two classes of azole pumps. These proteins carry compounds across the cell membrane with the help of some energy sources. Both have distinct protein domain parts, like the nucleotide-binding domain in the case of ABC pumps and the transmembrane domain in the case of MFS pumps. The genes encode these pumps are CDR1, CDR2, FLU1, MDR1 and MDR2. In the past decade, much work have been done to resolve the issue of resistance.13<\/sup><\/p>\n

Brescini and co-workers (2021) reviewed antifungal combinations against recalcitrant and resistant dermatophytes. These combinations were mainly focused on combination of two antifungal drugs or combination of one antifungal drug with some chemical entity. In this review, the combination of antifungal drugs with plant-based molecules\/phytoconstituents and the mechanism of combinatorial effect were less explored.12 \u00a0<\/sup><\/p>\n

In another review by Holmes et al<\/em>., (2016), all the targets for efflux pump against all the species, including Candida and dermatophytes were described. It was mainly focused on reversal of resistance by targeting these efflux pumps but the combination used to overcome resistance or for targeting the efflux pumps wasn\u2019t discussed.14<\/sup><\/p>\n

The present review mainly focuses on azoles, since these antifungal drugs play an essential role in treating dermatophytosis and candidiasis, where overexpression of drug efflux is a major cause of resistance. Different strategies like combination therapy suitable for reducing gene expression, blockage of efflux pumps and compitative substrates for efflux pumps proven effective against azole-resistant Candida and dermatophytes have been discussed in detail. The studies on the resistant of dermatophytes are less explored as compared to Candida. It needs immediate scientific intervention and attention before the disease becomes a pandemic.<\/p>\n

Materials and Methods<\/strong><\/p>\n

This systematic review was conducted as per the latest PRISMA guidelines [Fig: 2]. The published articles were exhaustively searched on PubMed and Google scholar during 23rd<\/sup> December 2021 to 14th<\/sup> March 2022. Different search strings like \u201cantifungal resistance,\u201d \u201ccombination used for overcoming,\u201d etc were used while retrieving the articles. Consensus for all the discrepancies which occurred during the process of inclusion of papers was reached through discussion. The inclusion criteria were papers that focussed mainly on antifungal resistance. Another inclusion criterion was the articles that focussed on the combination of antifungal drugs with phytoconstituent or the combination that focussed primarily in efflux pump blockage. The exclusion criteria were the papers that didn\u2019t refer to dermatophyte or candida resistance, unreachable publications and the ones that didn\u2019t specify the species name.<\/p>\n\n\n\n
\"Vol20No1_Eff_Ais_fig2\"<\/a><\/td>\nFigure 2: Flowchart of the different phases of article selection of the review.<\/strong><\/p>\n

Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Results and Discussion<\/strong><\/p>\n

A total of 61832 articles were initially identified (Figure 2). The articles published from 2010 to 2022 were selected through further screening. The exclusion was done based on papers that didn\u2019t focus on resistance, which didn’t refer to dermatophytes or related species. Other exclusions were those papers that were out of the scope of this review. Total of sixteen articles were selected for the review. Out of 16 article 14 includes combinational therapy against resistant strains of Candida<\/em>, only 2 articles were found to be based on combinational therapy against resistant strains of dermatophytes.<\/p>\n

Combination against the resistant strain of Candida isolates<\/em><\/strong><\/p>\n

In recent years, a number of studies have been published on Candida<\/em> as compared to other fungus species. Combination therapy has shown reversal of azole resistance as evidenced from the reduction in MIC values, reduction in gene expression etc. Most of these studies contain in vitro<\/em> study data, thus lacking the studies of adverse effects associated with use of these drugs for antifungal therapies. A comprehensive account of antifungal combinations against azole resistant candida species with over expression of efflux pumps has been presented in Table 2.<\/p>\n

Fluconazole and ketorolac<\/strong><\/p>\n

Sayed et al<\/em>., (2021) conducted the sensitivity and efficacy study of fluconazole and ketarolac combination on resistance species of Candida albicans <\/em>(C.albicans<\/em>) obtained from acute myeloid leukemia patients and compared with monotherapy. They also confirmed the expression of efflux pump gene (CDR1, CDR2, MDR1) by real-time PCR on clinical isolates of C.albicans<\/em>, which are responsible for resistance development. They reported a drastic decrease in the minimum inhibitory concentration of fluconazole and ketarolac combination as compared to fluconazole and ketarolac alone as 0.3-1.25 \u00b5g\/ml, 160 \u00b5g\/ml and 10 \u00b5g\/ml respectively. Reported FICI (Fractional inhibitory concentration index) value (0.25) confirms synergism.15<\/sup><\/p>\n

Fluconazole and Ginko biloba<\/em><\/strong><\/p>\n

Yiman et al<\/em>.,(2020) conducted a study where phytoconstituent like Ginkolide B was combined with fluconazole and its effect on fluconazole-resistant C. albicans<\/em> was observed. Fluconazole alone had no effect on an Azole-resistant strain of C. albicans<\/em>, as seen by its MIC value (>256 g\/ml). The MIC was lowered from >512 g\/ml to 0.25 g\/ml in conjunction with Ginko biloba<\/em>, indicating synergism. They also discussed that calcium homeostasis is the basis for the average growth and pathogenicity of C. albicans.<\/em> The intracellular calcium concentration in these strains was altered, which can be the base of synergism. Yet the mechanism is not mentioned correctly. A fluorescent assay was performed, and the result indicated enhanced uptake of fluconazole when given in combination with ginkolide.16<\/sup><\/p>\n

Eugenol and methyleugenol with fluconazole<\/strong><\/p>\n

Ahmed et al<\/em>., (2010) evaluated the efficacy of two bioactive compounds found in essential oil, eugenol and methyleugenol, alone and in combination with fluconazole against fluconazole resistant clinical Candida<\/em> isolates. The method used to confirm the resistance has not been discussed. Even though both the bioactive compounds were effective against resistant species, methyl eugenol was much more effective than eugenol. The MIC value of eugenol and methyleugenol against resistant strain ranged from 475 \u2013 500 \u00b5g\/ml and 340-350 \u00b5g\/ml, while in the combination ranged from 110\u2013120 \u00b5g\/ml and 70-90 \u00b5g\/ml, respectively. The high fungicidal effect of these compounds on combination with fluconazole was confirmed using a disc diffusion assay. Proper mechanisms regarding how this combination helps to overcome resistance have not been discussed. But it was reported that the lipophilic character of eugenol and methyleugenol might enable these compounds to enter into the membrane lipid bilayer altering the fluidity and permeability, thus interfering with enzyme activity which helps in cell wall synthesis.17<\/sup><\/p>\n

Monoterpenes with fluconazole<\/strong><\/p>\n

Ahmed et al<\/em>., (2012) conducted a study where the efficacy of the combination of thymol and carvacrol with fluconazole was tested against fluconazole-resistant clinical Candida<\/em> isolates. MIC values of thymol, carvacrol, and fluconazole for fluconazole-sensitive and fluconazole-resistant strains of C.<\/em> albicans<\/em> were 90-150\u00b5g\/ml, 50-100\u00b5g\/ml, and 2.5-7.5\u00b5g\/ml, respectively. Using combination MIC was reduced to 21-32\u00b5g\/ml, 7-23\u00b5g\/ml, 0.5-2\u00b5g\/ml respectively. MIC values and wider inhibition zones revealed that all of the isolates were sensitive to monoterpenes and their combination. The sensitivity index was comparatively larger for the carvacrol fluconazole combination [3.2+0.05]. A reduction in the efflux activity was confirmed by using a fluorescent assay. RT PCR (Real time polymerase chain reaction) was used to confirm the decrease in the quantity of CDR and MDR genes that encode for efflux pumps and are responsible for fluconazole resistance. C. albicans<\/em> resistant strains overexpress just CDR1 and not MDR1, whereas Candida glabrata<\/em> and Candida krusei<\/em> overexpress both CDR1 and MDR1.18<\/sup><\/p>\n

Fluoxetine with fluconazole<\/strong><\/p>\n

Oliveira et al<\/em>., (2014) investigated the efficacy of fluoxetine alone and in combination with fluconazole against Candida strains isolated from patients with vulvo vaginal candidiasis. The combination resulted in a reduction in MIC values (decreased up to 64 fold). Among the tested strains, six of the candida species showed a synergistic effect, among which 4 of them were resistant to fluconazole whereas the remaining showed an indifferent effect which was evident from fractional inhibitory index values between 0.15-0.31 and 0.63-1, respectively.19<\/sup><\/p>\n

Calcineurin inhibitors with fluconazole<\/strong><\/p>\n

Kaya et al<\/em>., 2021 reported the calcineurin mutants exhibited increased susceptibility towards antifungal drugs, including azoles. Calcineurin inhibitors such as cyclosporin A and tacrolimus demonstrated synergistic activity with fluconazole against various fungi, including C. albicans<\/em>. The interaction of cyclosporin A with azoles such as fluconazole and itraconazole against azole susceptible and resistant C. albicans<\/em>\u00a0was studied using the chequerboard method. Based on a fluorescent study, this combination inhibited C. albicans<\/em> growth and hyphal formation, which in turn inhibits biofilm formation. Similarly, tacrolimus in combination with fluconazole could reverse drug resistance. The synergistic activity was studied with the checkerboard method and time-killing test.20<\/sup><\/p>\n

Tetrandrine with fluconazole<\/strong><\/p>\n

Keyal et al<\/em>., 2017 evaluated that Tetrandrine (ancient Chinese medicine ), a dibenzylisoquinoline alkaloid increased the sensitivity of C. albicans<\/em> towards fluconazole. Both compounds had synergistic interactions. Tetrandrine could inhibit the expression of genes like MDR1, FLU1, CDR1, and CDR2 reducing the drug efflux and increasing intracellular azole accumulation. It also had antibiofilm activity and targeted sterol biosynthesis altering fluidity and permeability of cell membrane.21<\/sup><\/p>\n

Glucocorticoid with fluconazole<\/strong><\/p>\n

Wenwen et al<\/em>., 2017 combined glucocorticoids like dexamethasone and budesonide along with fluconazole. They exhibited synergistic activity against Candida <\/em>spp.<\/em> which was evident by FICI index of less than 0.5 but had no antifungal action when used alone. RTPCR results confirmed the reduction in expressions of drug-resistant genes like CDR1, CDR2, and MDR1, which indicates synergism and extracellular phospholipase activity. A critical virulence factor was also measured using the egg yolk agar method showed a reduction in virulence.22<\/sup><\/p>\n

Gentamycin with fluconazole<\/strong><\/p>\n

Lu et al<\/em>., 2017 combined gentamycin with fluconazole against resistant C. albicans<\/em> species. The combination reduced the MIC and FICI values by 0.13-0.14, confirming synergism. The rhodamine efflux assay was used to verify the reduction in efflux activity dose-dependently. A decrease in phospholipase activity also showed a reduction in the pathogenicity of the strains.23<\/sup><\/p>\n

Oridonin with azole<\/strong><\/p>\n

Chen et al<\/em>., 2020 used a combination of azole drugs (Itraconazole, Fluconazole) with oridonin against resistant C albicans<\/em> strain isolated from cancer patients. A reduction in MIC was observed. MIC of fluconazole and itraconazole decreased from >512\u00b5g\/ml and >8\u00b5g\/ml to <8 and <0.2\u00b5g\/ml, respectively. The resistance reversal mechanisms, namely inhibition of drug efflux and induction of apoptosis, were investigated by flow cytometry. Expression levels of the efflux pump-related genes CDR1 and CDR2 were assessed by RT-qPCR.24\u00a0<\/sup><\/p>\n

Antimicrobial photodynamic therapy with aloe-emodin<\/strong><\/p>\n

Leu et al<\/em>., 2019 evaluated the photodynamic effect of Aloe-emodin on drug-resistant C. albicans<\/em>. Aloe-emodin could effectively inactivate C. albicans<\/em> in a concentration-dependent manner in the presence of light. The uptake of aloe-emodin by cells was studied using confocal laser scanning microscopy. SEM and TEM analysis showed that therapy could induce the damage of the fungal cell wall, cytoplasm and nucleus.25<\/sup><\/p>\n

Curcumin with fluconazole<\/strong><\/p>\n

Gomez et al<\/em>., 2012 evaluated the capability of curcumin to sensitize the clinical fluconazole-resistant isolate of C. albicans<\/em>. The MIC was reduced from 256 \u00b5g\/l to <2\u00b5g\/l. Synergistic interaction was assessed using a checkerboard experiment. Efflux pump activity was evaluated using Nile red accumulation assay. 11\u00b5M of curcumin was able to restore Nile red accumulation indicating inhibition of efflux activity.26<\/sup><\/p>\n

Fluconazole with citral<\/strong><\/p>\n

In an investigation by Cadena et al<\/em>., 2022, citral, a phytochemical constituent of lemongrass oil, was found effective in combating Candida<\/em> infections when combined with fluconazole. Citral reduced the biofilm formation and the combination exhibited synergism against most of the strains tested with FICI 0.5. RNA analysis further revealed the efflux pump reduction encoded by MDR1. However, the results weren\u2019t conclusive about the expression of ERG11 gene. The expression of ERG11 gene weren\u2019t significant even though a slight upregulation was observed.27<\/sup><\/p>\n

Eucalyptal D with Fluconazole<\/strong><\/p>\n

Xu et al<\/em>., (2019) reported that Eucalyptal D (ED), significantly enhance the anticandidal activity of fluconazole (FLC) in treating FLC resistant C. albicans<\/em>. They performed, checkerboard microdilution assay, rhodamine 6G (R6G) efflux assay, and reverse transcription PCR analysis and reported that the combination shows a synergistic effect. It was hypothesized that ED was a substrate of efflux pump (Cdr1p and Cdr2p), actively flushed out in place of fluconazole in resistant C. Albicans<\/em>.28<\/sup><\/p>\n

Combination against resistant dermatophytes<\/strong><\/p>\n

A few studies have been published on antifungal combinations against azole resistant dermetophytes with over-expression of efflux pumps.29-30 <\/sup>These are detailed in the Table 3. Both the studies were conducted in vitro<\/em> and hence lacking in studies\/data on adverse effects.<\/p>\n

Essential oils with fluconazole<\/strong><\/p>\n

In a study Khan et al<\/em>., 2011 analyzed several essential oils and their active compounds like S. Aromaticum, C. Verum, C. Martini, Geraniol, Cinnamaldehyde etc. The strains A. ompounds<\/em> and T. rubrum<\/em> were tested for azole drug resistance and fluconazole showed higher resistance level\u00a0than itraconazole. Most of the essential oils showed intense activity against tested fungi, among which cinnamaldehyde showed the highest zone of inhibition against T.rubrum.<\/em> When combined with fluconazole, all the tested oils showed a significant synergistic interaction against T. Rubrum<\/em> and A.ompounds,<\/em> evident from FICI values. Among all the tested ones, cinnamaldehyde showed the highest degree of synergism. Its effect on ultrastructure was investigated further using TEM, and it was discovered that hyphal specimen treatment with cinnamaldehyde resulted in cell lysis as well as cytoplasmic disorganization.29<\/sup><\/p>\n

Protocatechuates with fluconazole<\/strong><\/p>\n

Luciana et al<\/em>., (2014) investigated the antifungal activity of protocatechuic acid 3,4 diacetoxybenzoic acid and its 14 alkyl derivative against clinical strains of T. rubrum<\/em> and T. metagrophytes<\/em> alone and in combination with fluconazole. Both these compounds are considered to have low antidermatophytic activity because of their very high MIC values (125mg\/ml and above). But addition of methyl groups\u00a0 to these compounds showed reduction in MIC values and increase in antifungal activity. The best MIC values were shown by pentyl, hexyl, heptyl, octyl, nonyl and decyl protocatechuate compounds ranging from 1.95 to 7.8mg\/ml. It was reported that carbon chains have a crucial role in antifungal and antioxidant activity, but the actual mechanism has not been discussed in the paper. FIC index of 0.49 showed additive and synergistic action of all the compounds in combination with fluconazole.30<\/sup><\/p>\n\n\n\n
\"Vol20No1_Eff_Ais_tab2\"<\/a><\/td>\nTable 2: Antifungal combinations against azole resistant Candida<\/em> species with over expression of efflux pumps<\/strong><\/p>\n

Click here to view Table<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
\"Vol20No1_Eff_Ais_tab3\"<\/a><\/td>\nTable 3: Antifungal combinations against azole resistant dermetophytes with over expression of efflux pumps<\/strong>Conclusions<\/strong>\u00a0<\/strong><\/p>\n

Click here to view Table<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The persistence and frequent recurrence of dermatophyte infections necessitate prolonged treatment. This leads to the risk of severe adverse effects and development of drug resistance. It has already been witnessed in systemic fungal infections caused by Candida<\/em> and the emergence of drug resistant strains among T.<\/em> rubrum<\/em>.<\/em> Most of the in vitro<\/em> studies have investigated the combination of azole antifungal agents with several other chemical compounds and phytochemicals. The association between an antifungal drug and plant extract, including essential oils, seems to evoke a particular interest. The reciprocal potentiation of the molecules upon combination makes these approaches particularly appealing against resistant strains. Although the intrinsic mechanisms of antifungal activity of these natural products have not been thoroughly investigated, several cell targets are simultaneously involved, thereby chances of occurrence of resistance remains minimal. Anti\u2013fungal studies indicate that an association of antifungal agents is influential, and it might be helpful in speeding up the microbiological healing of superficial infections. One of the major limitations with published studies is lack of sufficient evidences in support of combination therapy over treatment with single drug as a viable approach in minimizing the adverse effects associated with irrational use of individual drugs. In summary, antifungal combinations against dermatophytes and Candida<\/em> have gained considerable scientific interest over the years. To establish this approach as a reliable treatment option in clinical settings, additional studies are warranted.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

There are no conflict of interest.<\/p>\n

Reference <\/strong><\/p>\n

    \n
  1. Mishra L, Gupta S. Fluconazole and Curcumin Loaded Nanoemulsion Against Multiple Drug Resistance Dermatophytes. Biomed. Pharmacol. J., 14(4): 2085-2089 (2021).<\/li>\n
  2. Prasad R, Rawal MK. Efflux pump proteins in antifungal resistance. Front Pharmacol. 29(5):202 (2014)<\/li>\n
  3. Nair GG, Sathianarayanan S and Namboori K, Study of Using Syzygium Samarangese Against Azole Resistant Candida<\/em> Species- a Computational and Pharmacogenomic Approach. Proceedings of International Conference on Drug Discovery (ICDD) (2020)<\/li>\n
  4. Arun CS, Raju P, Lakshmanan V, Kumar A, Bal A, Kumar H. Emergence of Fluconazole-resistant Candida Infections in Diabetic Foot Ulcers: Implications for Public Health. Indian J. Community Med. ;44(1): S74-S76 (2019)<\/li>\n
  5. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev.;12(4):501-517 (1999).<\/li>\n
  6. Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed., 4(5): 305-10 (2005).<\/li>\n
  7. Kontoyiannis DP. Antifungal Resistance: An Emerging Reality and A Global Challenge. J. Infect. Dis. 15;216(3):S431-S435 (2017).<\/li>\n
  8. Ghannoum M. Azole Resistance in Dermatophytes: Prevalence and Mechanism of Action. J. Am. Podiatr Med. Assoc., 106(1): 79-86 (2016).<\/li>\n
  9. Yamada T, Yaguchi T, Tamura T, Pich C, Salamin K, Feuermann M, Monod M. Itraconazole resistance of Trichophyton rubrum mediated by the ABC transporter TruMDR2. Mycoses., 64(8): 936-946 (2021).<\/li>\n
  10. Martinez-Rossi NM, Bitencourt TA, Peres NTA, Lang EAS, Gomes EV, Quaresemin NR, Martins MP, Lopes L, Rossi A. Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus. Front Microbiol., 29(9): 1108 (2018).<\/li>\n
  11. Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet. Biol., 132:103255 (2019).<\/li>\n
  12. Brescini L, Fioriti S, Morroni G, Barchiesi F. Antifungal Combinations in Dermatophytes. J. Fungi (Basel)., 5;7(9): 727 (2021).<\/li>\n
  13. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh A, Upadhyaya G, Upadhyay S, Yadav P, Singh PK, Khillan V, Sachdeva N, Perlin DS, Meis JF. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob Chemother., 1;73(4): 891-899 (2018).<\/li>\n
  14. Holmes AR, Cardno TS, Strouse JJ, Ivnitski-Steele I, Keniya MV, Lackovic K, Monk BC, Sklar LA, Cannon RD. Targeting efflux pumps to overcome antifungal drug resistance. Future Med. Chem., 8(12): 1485-501 (2016).<\/li>\n
  15. Sayed SA, Hassan EAB, Abdel Hameed MR, Agban MN, Mohammed Saleh MF, Mohammed HH, Abdel-Aal AM, Elgendy SG. Ketorolac-fluconazole: A New Combination Reverting Resistance in\u00a0Candida albicans\u00a0from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study. J. Blood Med., 15;12: 465-474 (2021).<\/li>\n
  16. Li Y, Yang J, Li X, Su S, Chen X, Sun S, Li Y. The effect of Ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms. Int. J. Antimicrob Agents., ,56(2): 106030 (2020).<\/li>\n
  17. Ahmad A, Khan A, Khan LA, Manzoor N. In vitro synergy of eugenol and methyleugenol with fluconazole against clinical Candida isolates. J. Med. Microbiol., 59(10):1178-1184 (2010).<\/li>\n
  18. Ahmad A, Khan A, Manzoor N. Reversal of efflux mediated antifungal resistance underlies synergistic activity of two monoterpenes with fluconazole. Eur. J. Pharm Sci. 23;48(1-2): 80-6 (2013).<\/li>\n
  19. Oliveira AS, Gaspar CA, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Palmeira-de-Oliveira A. Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains. Antimicrob Agents Chemother., 58(7): 4224-6 (2014).<\/li>\n
  20. \u015een Kaya S, Kiraz N, Bari\u015f A, Turan D, \u00d6z Y, Da\u011f \u0130, Ayg\u00fcn G. Effects of calcineurin inhibitors, cyclosporine A and tacrolimus (FK506), on the activity of antifungal drugs against\u00a0Candida\u00a0spp. J. Med. Microbiol., 70(4) (2021).<\/li>\n
  21. Keyal U, Huang X, & Bhatta AK. Drug interaction of traditional Chinese medicines with fluconazole against fluconazole resistant strains of Candida albicans. Int. J. Clin. Exp. Med.. 2016. 22357-22362 (2016).<\/li>\n
  22. Sun W, Wang D, Yu C, Huang X, Li X, Sun S. Strong synergism of dexamethasone in combination with fluconazole against resistant Candida albicans mediated by inhibiting drug efflux and reducing virulence. Int. J. Antimicrob Agents., 50(3): 399-405 (2017).<\/li>\n
  23. Lu M, Yu C, Cui X, Shi J, Yuan L, Sun S. Gentamicin synergises with azoles against drug-resistant Candida albicans. Int. J. Antimicrob Agents., 51(1):107-114 (2018).<\/li>\n
  24. Chen H, Li H, Duan C, Song C, Peng Z, Li H, Shi W. Reversal of azole resistance in Candida albicans by oridonin. J Glob Antimicrob Resist., 24: 296-302 (2021).<\/li>\n
  25. Ma W, Liu C, Li J, Hao M, Ji Y, Zeng X. The effects of aloe emodin-mediated antimicrobial photodynamic therapy on drug-sensitive and resistant Candida albicans. Photochem Photobiol Sci. 15;19(4): 485-494 (2020).<\/li>\n
  26. Garcia-Gomes AS, Curvelo JA, Soares RM, Ferreira-Pereira A. Curcumin acts synergistically with fluconazole to sensitize a clinical isolate of Candida albicans showing a MDR phenotype. Med Mycol., 50(1): 26-32 (2012).<\/li>\n
  27. Miranda-Cadena K, Marcos-Arias C, Perez-Rodriguez A, Cabello-Beitia I, Mateo E, Sevillano E, Madariaga L, Quind\u00f3s G, Eraso E.\u00a0In vitro\u00a0and\u00a0in vivo\u00a0anti-Candida\u00a0activity of citral in combination with fluconazole. J Oral Microbiol., 2;14(1): 2045813 (2022).<\/li>\n
  28. Xu J, Liu R, Sun F, An L, Shang Z, Kong L, Yang M. Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant\u00a0Candida albicans\u00a0by Competitively Inhibiting Efflux Pump. Front Cell Infect. Microbiol., 20;9: 211 (2019).<\/li>\n
  29. Khan MSA, and Ahmad I. “In vitro antifungal activity of oil of Cymbopogon citratus and citral alone and in combination with fluconazole against azole-resistant strains of Aspergillus fumigatus and Trichophyton rubrum.” Phcog Commn., 3.3: 29 (2013).<\/li>\n
  30. Soares LA, Gullo FP, Sardi Jde C, Pitangui Nde S, Costa-Orlandi CB, Sangalli-Leite F, Scorzoni L, Regasini LO, Petr\u00f4nio MS, Souza PF, Silva DH, Mendes-Giannini MJ, Fusco-Almeida AM. Anti-trichophyton activity of protocatechuates and their synergism with fluconazole. Evid Based Complement Alternat Med., 2014: 957860 (2014).<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction The development of resistance against antifungal therapy is the […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[105],"tags":[],"class_list":["post-47586","post","type-post","status-publish","format-standard","hentry","category-vol16no1"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/47586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=47586"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/47586\/revisions"}],"predecessor-version":[{"id":48363,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/47586\/revisions\/48363"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=47586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=47586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=47586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}